UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
June 1, 2011
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] |
No [X] |
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________
Company Announcement
31 May 2011
Total number of voting rights and share capital in Novo Nordisk A/S as of 31 May 2011
In accordance with Section 6 of the Danish Statutory Order on Issuers Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of the month where changes have occurred.
Referring to Company Announcement no 26/2011 dated 2 May 2011, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 31 May 2011.
|
Number of shares |
Nominal value |
Number of votes |
|
(nominal value DKK 1) |
(DKK) |
|
|
|
|
|
A shares |
107,487,200 |
107,487,200 |
107,487,200,000 |
B shares |
472,512,800 |
472,512,800 |
47,251,280,000 |
Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 31,400 employees in 74 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
Company Announcement no 34 / 2011 |
Page 1 of 2 |
|||
|
||||
Novo Nordisk A/S Corporate |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 Telefax: +45 4444 2314 |
Internet: novonordisk.com |
CVR Number: 24256790 |
Further information: |
|
|
|
Media: |
Investors: |
|
|
Outside North America: |
Klaus Bülow Davidsen |
Anne Margrethe Hauge |
Tel: (+45) 4442 3176 |
Tel: (+45) 4442 3450 |
klda@novonordisk.com |
amhg@novonordisk.com |
|
|
|
|
Jannick Lindegaard |
|
Tel: (+45) 4442 4765 |
|
jlis@novonordisk.com |
|
|
In North America: |
|
Ken Inchausti |
Frank Daniel Mersebach |
Tel: (+1) 609 514 8316 |
Tel: (+45) 4442 0604 |
kiau@novonordisk.com |
fdni@novonordisk.com |
Company Announcement no 34 / 2011 |
Page 2 of 2 |
|||
|
||||
Novo Nordisk A/S Corporate |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 Telefax: +45 4444 2314 |
Internet: novonordisk.com |
CVR Number: 24256790 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: June 1, 2011 |
NOVO NORDISK A/S Lars Rebien Sørensen, President and Chief Executive Officer |